In vitro activity in patients with skin infections1
Ceftaroline was active against the gram-positive isolates collected. Susceptibility of ESBL-negative gram-negative isolates showed regional variations.1
PP-ZFO-IND-0225
Ceftaroline achieved PTAs for bacteriostatic and bactericidal targets2
Ceftaroline achieved PTAs >99.9% for bacteriostatic and bactericidal targets at the MIC90 (1 mg/L), whereas the comparators failed to achieve PTAs >90% for bacteriostatic or bactericidal targets, even when clinical doses were increased beyond the recommended level(s).2
PP-ZFO-IND-0249
Exploratory analyses of the Phase 3 COVERS trial3
Ceftaroline fosamil is a beta-lactam antibiotic with in vitro activity against MRSA. The Phase 3 COVERS study demonstrated the efficacy and safety of a high-dose regimen of ceftaroline fosamil (600 mg 2-hour IV infusions q8h) versus vancomycin plus aztreonam in hospitalised patients with cSSTI and underlying comorbidities.3
PP-ZFO-IND-0254
Ceftaroline fosamil showed high efficacy/effectiveness in patients with any type of pneumonia with a good safety profile4
Pneumonia is a relevant clinical and public health issue worldwide frequently associated with infections caused by MDR pathogens. On the basis of this analysis, ceftaroline fosamil showed high efficacy/effectiveness in patients with any type of pneumonia with a good safety profile.4
PP-ZFO-IND-0250
A real-world 2-centre experience in Italy and Spain5
Ceftaroline is one of the latest additions to the armamentarium for treating CAP. Considering its spectrum of activity, ceftaroline could represent an important therapeutic option for SCAP.5
PP-ZFO-IND-0251
| Header | ||
|---|---|---|
| Header | Header | Header |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
CAP, community-acquired pneumonia; COVERS, CeftarOline versus Vancomycin and aztrEonam tReating cSSTI; cSSTI, complicated skin and soft tissue infection; ESBL, extended-spectrum beta-lactamase; ICU, intensive care unit; IV, intravenous; MDR, multidrug resistant; MIC90, minimum inhibitory concentration at which 90% of the isolates are inhibited; MRSA, methicillin-resistant Staphylococcus aureus; PTA, probability of target attainment; q8h; every 8 hours; SCAP, severe community-acquired pneumonia.
References:
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.